Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone

Schizophrenia Research

Volumn 107, Issue 2-3, 2009, Pages 134-138

  Kelly, Deanna L ^a   Wehring, Heidi J ^a   Linthicum, Jared ^a   Feldman, Stephanie ^a   McMahon, Robert P ^a   Love, Raymond C ^b   Wagner, Tara ^a   Shim, Joo Cheol ^c   Fowler, David R ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c Inje University College of Medicine   (South Korea)

^d NONE

Author keywords

Autopsy; Cardiomyopathy; Cardiovascular; Clozapine; Mortality

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; ATHEROSCLEROSIS; AUTOPSY; BODY MASS; BODY WEIGHT; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HEART DEATH; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; METABOLIC DISORDER; MOOD DISORDER; MORTALITY; MYOCARDITIS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CASE-CONTROL STUDIES; CAUSE OF DEATH; CLOZAPINE; CORONARY ARTERY DISEASE; CORONARY VESSELS; ENDOMYOCARDIAL FIBROSIS; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MARYLAND; MIDDLE AGED; MYOCARDIUM; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; WAIST-HIP RATIO;

EID: 58249089282     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.10.020     Document Type: Article

References (29)

1. Abidi S., and Bhaskara S.M. From chlropromazine to clozapine-antipsychotic adverse effects and the clinician's dilemma. Can. J. Psychiatry 48 11 (2003) 749-755
2. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., and Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 11 (1999) 1686-1696
3. Buckman R.W., and Malan R.D. Clozapine for refractory schizophrenia: the Illinois experience. J. Clin. Psychiatry 60 suppl 1 (1999) 18-22
4. Casey D.E. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am. J. Med. 118 Suppl 2 (2005) 15S-22S
5. Citrome L., Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., McEvoy J., Cooper T.B., Chakos M., and Lieberman J.A. Effects of clozapine, olanzapine, risperidone and haloperidol on hostility among patients with schizophrenia. Psychiatr. Serv. 52 11 (2001) 1510-1514
6. Conley R.R., and Kelly D.L. Management of treatment resistance in schizophrenia. Biol. Psychiatry 50 11 (2001) 898-911
7. Conley R.R., Kelly D.L., Lambert T.J., and Love R.C. Comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatr. Serv. 56 3 (2005) 320-323
8. Coulter D.M., Bate A., Meyboom R.H., Lindquist M., and Edwards I.R. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: a data mining study. B.M.J. 322 7296 (2001) 1207-1208
9. Drici M.D., and Priori S. Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiol. Drug Saf. 16 8 (2007) 882-890
10. Essock S.M., Frisman L.K., Covell N.H., and Hargreaves W.A. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch. Gen. Psychiatry 57 10 (2000) 987-994
11. Fayak M., Flowers C., Signorelli D., and Simpson G. Underuse of evidence-based treatments in psychiatry. Psychiatr. Serv. 54 (2003) 1453-1456
12. Gitlin M. Treatment-resistant bipolar disorder. Mol. Psychiatry 11 3 (2006) 227-240
13. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., Lambert S., D'Agostino R.B., Stroup T.S., Davis S., and Lieberman J.A. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 80 1 (2005) 45-53
14. Haas S.J., Hill R., Krum H., Liew D., Tonkin A., Demos L., Stephan K., and McNeil J. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Safety 30 1 (2007) 47-57
15. Hennekens C.H., Hennekens A.R., Hollar D., and Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 150 6 (2005) 1115-1121
16. Hunt S.A., and American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 46 6 (2005) 1-82
17. Iqbal M.M., Rahman A., Husain Z., Mahmud S.Z., Ryan W.G., and Feldman J.M. Clozapine: a clinical review of adverse effects and management. Ann. Clin. Psychiatry 15 1 (2003) 33-48
18. Kelly D.L., Kreyenbuhl J., Buchanan R.W., and Malhotra A.K. Why not clozapine?. Clin. Schiz. Rel. Psychoses. 1 1 (2007) 92-95
19. Kelly D.L., Kreyenbuhl J., Dixon L., Love R.C., Medoff D., and Conley R.R. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr. Bull. 33 5 (2007) 1221-1224
20. Krakowski M.I., Czobor P., Citrome L., Bark N., and Cooper T.B. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 63 16 (2006) 622-629
21. Lieberman J.A. Maximizing clozapine therapy: managing side effects. J. Clin. Psychiatry 59 suppl 3 (1998) 38-43
22. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K., and CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163 4 (2006) 600-610
23. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Bourgeois M., Chouinard G., Islam M.Z., Kane J., Krishnan R., Lindenmayer J.P., Potkin S., and International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60 (2003) 82-91
24. Merrill D.B., Dec G.W., and Goff D.C. Adverse cardiac effects associated with clozapine. J. Clin. Psychopharmacol. 25 1 (2005) 32-41
25. Rosenheck R., Cramer J., Allan E., Erdos J., Frisman L.K., Xu W., Thomas J., Henderson W., and Charney D. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory schizophrenia. Arch. Gen. Psychiatry 56 6 (1999) 565-572
26. Taylor D.M., Young C., and Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J. Clin. Psychiatry 64 1 (2003) 30-34
27. Wehmeier P.M., Heiser P., and Remschmidt H. Myocarditis, pericarditis, and cardiomyopathy in patients treated with clozapine. J. Clin. Pharm. Ther. 30 (2005) 91-96
28. Wong C., and Marwick T.H. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat. Clin. Pract. Cardiovasc. Med. 4 8 (2007) 436-443
29. Wong C., and Marwick T.H. Obesity cardiomyopathy: diagnosis and therapeutic implications. Nat. Clin. Pract. Cardiovasc. Med. 4 9 (2007) 480-490